Form D · Biotechnology

Evia Bio, Inc.

Minneapolis, MN · CIK 0001954759

Offering snapshot reported Sep 28, 2026 · SEC filing

Reported sold
$5.45M
Offering amount: $5.45M
Investors reported
19
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 14, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 28, 2026Initial$5,453,532No comparison19SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-598967
In addition to the shares sold for cash in the offering $3,453,532.33 of Convertible Promissory Notes converted into shares of the Issuer's Preferred Stock.

Source: Form D, filed Sep 28, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jeffrey Allen Director, Executive
Marc Centrella Director
Scott Fisher Director
Allison Hubel Director
Troy Wichterman Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2001 6th Street Se, Room 2 434 Bench 33
Minneapolis, MN, 55455
Phone: 414 852-0037